Anticipated 0 11 0 11 O
lifespan 12 20 12 20 B-clinical_variable
greater 21 28 21 28 O
than 29 33 29 33 O
12 34 36 34 36 B-lower_bound
weeks 37 42 37 42 I-lower_bound

Eastern 0 7 43 50 B-clinical_variable
Cooperative 8 19 51 62 I-clinical_variable
Oncology 20 28 63 71 I-clinical_variable
Group 29 34 72 77 I-clinical_variable
( 35 36 78 79 I-clinical_variable
ECOG 36 40 79 83 I-clinical_variable
) 40 41 83 84 I-clinical_variable
performance 42 53 85 96 I-clinical_variable
status 54 60 97 103 I-clinical_variable
of 61 63 104 106 O
0 64 65 107 108 B-lower_bound
- 65 66 108 109 O
2 66 67 109 110 B-upper_bound

Histological 0 12 111 123 O
confirmation 13 25 124 136 O
of 26 28 137 139 O
melanoma 29 37 140 148 B-cancer
will 38 42 149 153 O
be 43 45 154 156 O
required 46 54 157 165 O
by 55 57 166 168 O
previous 58 66 169 177 B-treatment
biopsy 67 73 178 184 I-treatment
or 74 76 185 187 O
cytology 77 85 188 196 B-treatment

Inhaled 0 7 197 204 B-treatment
corticosteroids 8 23 205 220 I-treatment
are 24 27 221 224 O
acceptable 28 38 225 235 O

Laboratory 0 10 236 246 O
values 11 17 247 253 O
( 18 19 254 255 O
to 19 21 255 257 O
be 22 24 258 260 O
performed 25 34 261 270 O
within 35 41 271 277 O
28 42 44 278 280 B-upper_bound
days 45 49 281 285 I-upper_bound
of 50 52 286 288 O
enrollment 53 63 289 299 O
) 63 64 299 300 O
outside 65 72 301 308 O
of 73 75 309 311 O
protocol 76 84 312 320 O
- 84 85 320 321 O
specified 85 94 321 330 O
ranges 95 101 331 337 O

Need 0 4 338 342 O
for 5 8 343 346 O
chronic 9 16 347 354 O
steroids 17 25 355 363 B-treatment

No 0 2 364 366 O
active 3 9 367 373 B-chronic_disease
bleeding 10 18 374 382 I-chronic_disease

Other 0 5 383 388 O
active 6 12 389 395 O
metastatic 13 23 396 406 B-cancer
cancer 24 30 407 413 I-cancer
requiring 31 40 414 423 O
treatment 41 50 424 433 B-treatment

Patients 0 8 434 442 O
must 9 13 443 447 O
be 14 16 448 450 O
â‰¥ 17 18 451 452 O
18 19 21 453 455 B-lower_bound
years 22 27 456 461 I-lower_bound
of 28 30 462 464 O
age 31 34 465 468 B-age

Patients 0 8 469 477 O
who 9 12 478 481 O
have 13 17 482 486 O
previously 18 28 487 497 O
received 29 37 498 506 O
a 38 39 507 508 O
galectin 40 48 509 517 B-treatment
antagonist 49 59 518 528 I-treatment

Patients 0 8 529 537 O
who 9 12 538 541 O
have 13 17 542 546 O
radiographic 18 30 547 559 O
progression 31 42 560 571 O
using 43 48 572 577 O
Response 49 57 578 586 O
Evaluation 58 68 587 597 O
Criteria 69 77 598 606 O
In 78 80 607 609 O
Solid 81 86 610 615 O
Tumors 87 93 616 622 O
( 94 95 623 624 O
RECIST 95 101 624 630 O
) 101 102 630 631 O
currently 103 112 632 641 O
on 113 115 642 644 O
pembrolizumab 116 129 645 658 B-treatment
are 130 133 659 662 O
also 134 138 663 667 O
eligible 139 147 668 676 O

Patients 0 8 677 685 O
with 9 13 686 690 O
a 14 15 691 692 O
history 16 23 693 700 O
of 24 26 701 703 O
psychiatric 27 38 704 715 B-chronic_disease
illness 39 46 716 723 I-chronic_disease
must 47 51 724 728 O
be 52 54 729 731 O
judged 55 61 732 738 O
able 62 66 739 743 O
to 67 69 744 746 O
understand 70 80 747 757 O
fully 81 86 758 763 O
the 87 90 764 767 O
investigational 91 106 768 783 O
nature 107 113 784 790 O
of 114 116 791 793 O
the 117 120 794 797 O
study 121 126 798 803 O
and 127 130 804 807 O
the 131 134 808 811 O
risks 135 140 812 817 O
associated 141 151 818 828 O
with 152 156 829 833 O
the 157 160 834 837 O
therapy 161 168 838 845 B-treatment

Patients 0 8 846 854 O
with 9 13 855 859 O
active 14 20 860 866 O
autoimmune 21 31 867 877 B-chronic_disease
disease 32 39 878 885 I-chronic_disease
except 40 46 886 892 O
for 47 50 893 896 O
autoimmune 51 61 897 907 B-chronic_disease
thyroiditis 62 73 908 919 I-chronic_disease
or 74 76 920 922 O
vitiligo 77 85 923 931 B-chronic_disease

Patients 0 8 932 940 O
with 9 13 941 945 O
active 14 20 946 952 B-chronic_disease
infection 21 30 953 962 I-chronic_disease
requiring 31 40 963 972 O
antibiotics 41 52 973 984 B-treatment

Patients 0 8 985 993 O
with 9 13 994 998 O
history 14 21 999 1006 O
of 22 24 1007 1009 O
colitis 25 32 1010 1017 B-chronic_disease

Patients 0 8 1018 1026 O
with 9 13 1027 1031 O
metastatic 14 24 1032 1042 B-cancer
or 25 27 1043 1045 I-cancer
unresectable 28 40 1046 1058 I-cancer
melanoma 41 49 1059 1067 I-cancer
for 50 53 1068 1071 O
whom 54 58 1072 1076 O
treatment 59 68 1077 1086 B-treatment
with 69 73 1087 1091 O
pembrolizumab 74 87 1092 1105 B-treatment
is 88 90 1106 1108 O
indicated 91 100 1109 1118 O

Patients 0 8 1119 1127 O
with 9 13 1128 1132 O
non 14 17 1133 1136 B-cancer
- 17 18 1136 1137 I-cancer
small 18 23 1137 1142 I-cancer
cell 24 28 1143 1147 I-cancer
lung 29 33 1148 1152 I-cancer
cancer 34 40 1153 1159 I-cancer
for 41 44 1160 1163 O
whom 45 49 1164 1168 O
treatment 50 59 1169 1178 B-treatment
with 60 64 1179 1183 I-treatment
pembrolizumab 65 78 1184 1197 I-treatment
is 79 81 1198 1200 O
indicated 82 91 1201 1210 O

Patients 0 8 1211 1219 O
with 9 13 1220 1224 O
squamous 14 22 1225 1233 B-cancer
cell 23 27 1234 1238 I-cancer
carcinoma 28 37 1239 1248 I-cancer
of 38 40 1249 1251 O
the 41 44 1252 1255 O
head 45 49 1256 1260 O
and 50 53 1261 1264 O
neck 54 58 1265 1269 O
for 59 62 1270 1273 O
whom 63 67 1274 1278 O
treatment 68 77 1279 1288 B-treatment
with 78 82 1289 1293 I-treatment
pembrolizumab 83 96 1294 1307 I-treatment
is 97 99 1308 1310 O
indicated 100 109 1311 1320 O

Patients 0 8 1321 1329 O
with 9 13 1330 1334 O
untreated 14 23 1335 1344 O
brain 24 29 1345 1350 B-cancer
metastases 30 40 1351 1361 I-cancer
. 40 41 1361 1362 O
Patients 42 50 1363 1371 O
with 51 55 1372 1376 O
treated 56 63 1377 1384 O
brain 64 69 1385 1390 O
metastases 70 80 1391 1401 O
who 81 84 1402 1405 O
demonstrate 85 96 1406 1417 O
control 97 104 1418 1425 O
of 105 107 1426 1428 O
brain 108 113 1429 1434 O
metastases 114 124 1435 1445 O
with 125 129 1446 1450 O
follow 130 136 1451 1457 O
- 136 137 1457 1458 O
up 137 139 1458 1460 O
imaging 140 147 1461 1468 O
4 148 149 1469 1470 B-lower_bound
or 150 152 1471 1473 O
more 153 157 1474 1478 O
weeks 158 163 1479 1484 O
after 164 169 1485 1490 O
initial 170 177 1491 1498 O
therapy 178 185 1499 1506 B-treatment
are 186 189 1507 1510 O
eligible 190 198 1511 1519 O

Pregnant 0 8 1520 1528 B-pregnancy
or 9 11 1529 1531 O
lactating 12 21 1532 1541 O
women 22 27 1542 1547 B-gender
, 27 28 1547 1548 O
as 29 31 1549 1551 O
treatment 32 41 1552 1561 B-treatment
involves 42 50 1562 1570 O
unforeseeable 51 64 1571 1584 O
risks 65 70 1585 1590 O
to 71 73 1591 1593 O
the 74 77 1594 1597 O
embryo 78 84 1598 1604 O
or 85 87 1605 1607 O
fetus 88 93 1608 1613 O

Unresolved 0 10 1614 1624 O
immune 11 17 1625 1631 O
- 17 18 1631 1632 O
mediated 18 26 1632 1640 O
pneumonitis 27 38 1641 1652 B-chronic_disease
, 38 39 1652 1653 O
diarrhea 40 48 1654 1662 B-chronic_disease
, 48 49 1662 1663 O
elevation 50 59 1664 1673 O
of 60 62 1674 1676 O
hepatocellular 63 77 1677 1691 O
enzymes 78 85 1692 1699 O
or 86 88 1700 1702 O
other 89 94 1703 1708 O
toxicities 95 105 1709 1719 O
requiring 106 115 1720 1729 O
greater 116 123 1730 1737 O
than 124 128 1738 1742 O
physiological 129 142 1743 1756 B-treatment
replacement 143 154 1757 1768 I-treatment
doses 155 160 1769 1774 I-treatment
of 161 163 1775 1777 I-treatment
steroids 164 172 1778 1786 I-treatment

Women 0 5 1787 1792 B-gender
of 6 8 1793 1795 O
childbearing 9 21 1796 1808 O
potential 22 31 1809 1818 O
must 32 36 1819 1823 O
have 37 41 1824 1828 O
a 42 43 1829 1830 O
serum 44 49 1831 1836 B-pregnancy
or 50 52 1837 1839 I-pregnancy
urine 53 58 1840 1845 I-pregnancy
pregnancy 59 68 1846 1855 I-pregnancy
test 69 73 1856 1860 O
performed 74 83 1861 1870 O
within 84 90 1871 1877 O
72 91 93 1878 1880 B-upper_bound
hours 94 99 1881 1886 I-upper_bound
prior 100 105 1887 1892 I-upper_bound
to 106 108 1893 1895 O
the 109 112 1896 1899 O
start 113 118 1900 1905 O
of 119 121 1906 1908 O
protocol 122 130 1909 1917 O
treatment 131 140 1918 1927 B-treatment

